Intelligent Bio Solutions Inc.

NasdaqCM:INBS Stock Report

Market Cap: US$6.6m

Intelligent Bio Solutions Future Growth

Future criteria checks 2/6

Intelligent Bio Solutions is forecast to grow earnings and revenue by 14.5% and 34.4% per annum respectively while EPS is expected to grow by 34.7% per annum.

Key information

14.5%

Earnings growth rate

34.69%

EPS growth rate

Medical Equipment earnings growth17.2%
Revenue growth rate34.4%
Future return on equityn/a
Analyst coverage

Low

Last updated09 Sep 2026

Recent future growth updates

Recent updates

Analysis Article • Jun 18

The Future of Drug Testing? Fingerprint Tech From Intelligent Bio Solutions (NASDAQ:INBS) Shows Serious Promise

Intelligent Bio Solutions has a new way to test for drugs using fingerprints: it’s quick, portable, and doesn’t require urine cups or saliva swabs. With commercial traction in 24 countries and over 450 active accounts, INBS is now targeting the U.S. market, where over 55 million drug tests are performed annually.
Seeking Alpha • Oct 04

GBS acquires Intelligent Fingerprinting in all-stock deal

GBS (NASDAQ:GBS) said Tuesday it acquired Intelligent Fingerprinting (IFP), expanding the GBS platform of rapid, non-invasive diagnostic testing technologies and its geographical reach. GBS also began the process of changing its corporate name. GBS issued ~3M shares and ~2.4M series C convertible preferred shares to IFP shareholders. Up to 1.6M preferred shares have been reserved for issuance to IFP's shareholders and lenders. Each preferred share is convertible into three GBS shares. Former IFP shareholders entered into a 12-month lock-up agreement on sales of GBS shares and preferred stock issued under the deal. Former majority IFP shareholders have the right to name two board members to GBS' board. With the acquisition, GBS gains access to IFP's product portfolio, current customer base, and manufacturing facility in the U.K. - which complements GBS' development of its own facility at the University of Newcastle, Australia. GBS in Jun. announced an exclusive deal to acquire IFP.
Seeking Alpha • Aug 31

GBS GAAP EPS of -$0.57, revenue of $0.44M

GBS press release (NASDAQ:GBS): FY GAAP EPS of -$0.57. Revenue of $0.44M (-77.8% Y/Y). As of June 30, 2022, the Company’s cash, cash equivalents and marketable securities totaled approximately $8.2 million, compared to approximately $12.6 million on June 30, 2021.
Seeking Alpha • Aug 31

GBS Inc.: Can Its Technology Come Through?

GBS is a biotechnology company aiming to utilize saliva as a medium for developing non-invasive diagnostic tests. The companies pipeline products are targeting both the COVID-19 and Diabetes markets. GBS currently trades at around $3, which is an attractive entry point for investors. However - The high technological risk associated with its technology outweighs the low entry point. Technological Risk mainly stems from the fact that scientific literature disagrees over the reliability and accuracy of using saliva as a diagnostic medium.
Seeking Alpha • Aug 09

GBS Inc.: Pioneering Non-Invasive, Real-Time Diagnostic Testing

GBS Inc. is a developer of pioneering diagnostic platform adaptable to large unmet markets with multiple applications and indications. GBS has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company’s lead products are saliva glucose test and saliva SARS-CoV-2 antibody test.
Analysis Article • Jul 29

Is GBS (NASDAQ:GBS) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Earnings and Revenue Growth Forecasts

NasdaqCM:INBS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/202912-8N/AN/A1
6/30/20289-10N/AN/A1
6/30/20276-10N/AN/A1
6/30/20264-12-12-12N/A
3/31/20264-12-11-11N/A
12/31/20254-11-10-9N/A
9/30/20253-11-10-10N/A
6/30/20253-11-10-10N/A
3/31/20253-10-11-10N/A
12/31/20243-11-10-10N/A
9/30/20243-10-11-11N/A
6/30/20243-10-10-10N/A
3/31/20243-10-7-7N/A
12/31/20232-13-7-7N/A
9/30/20232-12-7-7N/A
6/30/20231-11-8-7N/A
3/31/20231-10-9-9N/A
12/31/20220-5-7-6N/A
9/30/2022N/A-8-6-5N/A
6/30/2022N/A-8-4-3N/A
3/31/20222-7-3-3N/A
12/31/20212-9-9-9N/A
9/30/20212-7-9-9N/A
6/30/20212-7-11-11N/A
3/31/20210-7-9-9N/A
12/31/20200-4-3-3N/A
9/30/20200-3-3-3N/A
6/30/20200-300N/A
3/31/20200-6N/A-5N/A
12/31/20190-7N/A-6N/A
9/30/20190-6N/A-5N/A
6/30/2019N/A-7N/A-6N/A
3/31/20190-6N/A-4N/A
12/31/2018N/A-5N/A-4N/A
9/30/2018N/A-6N/A-5N/A
6/30/2018N/A-5N/A-5N/A
3/31/20180-3N/A-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: INBS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: INBS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: INBS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: INBS's revenue (34.4% per year) is forecast to grow faster than the US market (13.5% per year).

High Growth Revenue: INBS's revenue (34.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if INBS's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/11 00:49
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2026/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Intelligent Bio Solutions Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey CohenLadenburg Thalmann & Company